Industry News
Biotechnology Industry News
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blunder
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blunder mbayer Thu, 05/05/2022 - 13:26
Intellia puts pedal to the metal as 3 new candidates prepped for clinic
Intellia puts pedal to the metal as 3 new candidates prepped for clinic aarmstrong Thu, 05/05/2022 - 10:26
BioCryst’s voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals
BioCryst's voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals mbayer Thu, 05/05/2022 - 10:21
Big pharma resisting temptation for biotech M&A spree until prices drop further
Big pharma resisting temptation for biotech M&A spree until prices drop further jwaldron Thu, 05/05/2022 - 09:53
Bavarian Nordic’s COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push
Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push ntaylor Thu, 05/05/2022 - 08:54
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospect
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospect ntaylor Thu, 05/05/2022 - 08:05
BerGenBio shifts focus from COVID—to COVID in new business strategy update
BerGenBio shifts focus from COVID—to COVID in new business strategy update aarmstrong Wed, 05/04/2022 - 13:57
Bancel has ‘never been as busy’ amid M&A talks as Moderna preps for life after COVID
Bancel has 'never been as busy' amid M&A talks as Moderna preps for life after COVID mbayer Wed, 05/04/2022 - 10:41
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug gmasson Wed, 05/04/2022 - 10:24
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision ntaylor Wed, 05/04/2022 - 09:28
Catalio reloads with $381M after financing Octant, Pheast
Catalio reloads with $381M after financing Octant, Pheast aarmstrong Wed, 05/04/2022 - 09:23
Biogen shoves Aduhelm to the side. It’s time for lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab aarmstrong Wed, 05/04/2022 - 08:22
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward ntaylor Wed, 05/04/2022 - 07:54
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships mbayer Tue, 05/03/2022 - 18:38
Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartis
Record-breaking 2021 revenue shows there's more to Swiss biotech sector than Roche, Novartis mbayer Tue, 05/03/2022 - 14:22
Another Pfizer gene therapy is free of FDA hold, but delay continues
Another Pfizer gene therapy is free of FDA hold, but delay continues gmasson Tue, 05/03/2022 - 11:00
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug jwaldron Tue, 05/03/2022 - 10:40
After a dismal last year, Sesen Bio grasps for alternatives to stay afloat
After a dismal last year, Sesen Bio grasps for alternatives to stay afloat mbayer Tue, 05/03/2022 - 10:18
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to be aarmstrong Tue, 05/03/2022 - 10:04
Early clinical data on psilocybin in anorexia point Compass to potential new opportunity
Early clinical data on psilocybin in anorexia point Compass to potential new opportunity ntaylor Tue, 05/03/2022 - 08:34